Do you need more information
Do you need more information
CMV, HHV-6, HHV-7, HHV-8 are responsible for a wide range of pathologies. That’s why it’s important to achieve optimized detection and monitoring of CMV, HHV-6, HHV-7 and HHV-8 infection. CMV HHV6,7,8 R-GENE® is an ideal solution, offering rapid and specific detection. You can detect infection prior to clinical symptoms, improving options for management; test patients during treatment to measure the effectiveness of treatment; and test after treatment to monitor for relapse. Plus – for added efficiency and comprehensiveness – use with many of the kits from the R-GENE® range allows you to detect various viruses from one sample or analyze various samples for one virus at the same time.
*coming soon
The CMV HHV6,7,8 R-GENE® assay is a ready-to-use molecular detection kit. Using real-time PCR after viral DNA extraction, it measures the viral load of CMV and HHV-6, and allows the detection of HHV-7 and HHV-8. It works by amplifying and simultaneously detecting specific regions of the CMV, HHV-6, HHV-7 and HHV-8 genomes using 5’ nuclease Taqman technology.
The CMV HHV6,7,8 R-GENE® kit is simple to use. Just add the extracted DNA sample to the ready-to-use PCR master mixes and start the reaction on the appropriate Real-Time PCR thermocycler, following optimized cycling program described in the “Instructions For Use”.
BIOMERIEUX, the blue logo, ARGENE®,R-GENE®, EASYMAG® and NUCLISENS® are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.
Any other name or trademark is the property of its respective owner.
Technical Specifications - CMV HHV6,7,8 R-GENE® (69-100B | |
---|---|
Principle of the test | Genomic detection and quantification of CMV and HHV-6 Genomic detection of HHV-7 and HHV-8 |
Ordering information | Reference 69-100B: CMV HHV6,7,8 R-GENE® Detection and Quantification kit Also available under reference 69-100: CMV HHV6,7,8 R-GENE® Detection and Quantification kit COMPLETE kit (includes 69-100B Detection and Quantification kit kit and ref. 67-000 DNA Extraction kit) Supplementary reagents: 69-100R6: HHV6 premix R-GENE® 69-100R7: HHV7 premix R-GENE® 69-100R8: HHV8 premix R-GENE® |
Technology | Real-Time PCR / 5‘ nuclease Taqman technology |
Gene target | CMV: gene coding for ppUL83 protein HHV-6: U57 gene HHV-7: U42 gene HHV-8: ORF26 gene |
Specimen* | Whole blood, Plasma, CSF, Amniotic Fluid, Serum, Urine, BAL, Biopsies |
Limit of Detection | CMV: LoD 95% : 446 Copies/ mL of whole blood sample HHV-6: LoD 95% : 555 Copies/mL of whole blood sample |
Dynamic Range of Quantification | CMV in whole blood sample: 9.43 log (Cp/mL) to 2.63 log Cp/mL) CMV in Amniotic Fluid sample: 9.43 log (Cp/mL) to 2.63 log Cp/mL) |
Controls included | Extraction + Inhibition control, Sensitivity control, negative control |
Results within | 75 minutes (extraction step not included) |
Reporting unit | Copies/mL |
Number of tests | 140 tests |
Storage conditions | -18°C/-22°C for reference 69-100B (Detection and Quantification kit) +2°C/+8°C for ref. 67-000 (DNA Extraction kit) |
Validated Extraction platform* Manual Automated |
QIAamp DNA Blood Mini kit QIAcube NucliSENS® easyMAG® MagNA Pure Compact MagNA Pure LC MagNA Pure 96 m2000sp VERSANT kPCR Molecular System SP QIAsymphony SP |
Validated Amplification platform* | Life Technologies (Applied Biosystems) LightCycler 1.0 LightCycler 2.0 LightCycler 480 System II RotorGene VERSANT kPCR Molecular System AD DX Real-Time system CFX96 Stratagene / Agilent |
Status | For in vitro diagnostic use, CE marking in Europe: |
* please inquire
What are CMV, HHV-6, HHV-7, HHV-8?
Cytomegalovirus (CMV), human herpesevirus-6 (HHV-6), human herpesevirus-7 (HHV-7) and human herpesevirus-8 (HHV-8) are viruses characterized by high seroprevalence (ranging from 50% to 100%, depending on the geographical region) that are responsible for a wide range of pathologies. The primary infection commonly occurs during young childhood. The viral dissemination in blood may lead to benign and rare clinical signs. CMV, HHV-6, HHV-7 and HHV-8 establish a lifelong dormant infection. However, the viruses often reactivate in the case of an immunosuppression.
Who is most at risk?
The severity of infection depends on the immune status of the host (e.g. AIDS patients and organ transplant patients are commonly known as fragile hosts). CMV is associated with neurological diseases and pneumopathy. In severe cases, it can lead to mortality in immunocompromised patients. HHV-6 and HH-7 are also very likely to be involved in opportunistic infections in immunocompromised patients. HHV-6 and HHV-7 most likely increase the secondary CMV infections through a process of cross reactivation. When primary infection occurs, HHV-6 is also suspected to be responsible for mononucleosic syndroma, lymphadenopathy and hepatitis. HHV-8 is associated with lymphoproliferative diseases such as Kaposi sarcoma, Castleman disease and some lymphomas.
What are the benefits of CMV, HHV-6, HHV-7, HHV-8 testing?
Real-Time PCR-based assays for CMV, HHV-6, HHV-7, HHV-8 enable rapid and specific detection prior to clinical symptoms to help improve outcomes – which is especially important for immunosuppressed patients. Testing helps keep track of the effectiveness of active treatment and can monitor for relapse after treatment.